
Pathology Outlines - CD10
2023年1月17日 · CD10+ aids in diagnosis but must exclude CD10+ diffuse large B cell lymphoma, Burkitt-like lymphoma with 11q aberration, high grade B cell lymphoma with MYC and BCL2 / BCL6 rearrangement (double / triple hit lymphoma) (75 - 90% CD10+) and B lymphoblastic leukemia / lymphoma (B ALL / LBL) (Am J Clin Pathol 2012;137:665, Am J Clin Pathol 2010;133 ...
Pathology Outlines - Stains & CD markers
Kidney: AMACR CAIX CD10 CK7 c-kit / CD117 fumarate hydratase INI1 / SMARCB1 MelanA PAX8 RCC SDHB SMA TFE3 vimentin WT1 Penis: CK5/6 and CK5 HPV p40 p63 Prostate: AMACR androgen receptor (AR) CK5/6 and CK5 ERG NKX3.1 p63 prostein (P501S) PSA PSAP PSMA Testis: AFP CD30 CK7 c-kit / CD117 D2-40 glypican 3 hCG inhibin OCT3/4 PLAP SALL4 Gyn
Pathology Outlines - Marginal zone-nodal
2021年9月28日 · Lymphoma cells are CD10 and BCL6 positive and coexpressing BCL2, although monocytoid component could show weak / absent CD10; Additional useful immunostains - HGAL, LMO2 and MEF2B are positive in FL, while MNDA and IRTA1 are positive in NMZL Small lymphocytic lymphoma (SLL): Occasional cases have perifollicular infiltration mimicking NMZL
Pathology Outlines - Renal cell carcinoma (RCC)
2022年2月16日 · A panel of immunohistochemistry stains show tumor cells to be positive for CD10 and RCC Ma, while being negative for CK7, CK20, PAX8, CD117 and CAIX. While the immunohistochemistry profile is not entirely concordant with a renal primary, especially with negative PAX8 and CAIX, the positivity of both CD10 and RCC Ma would suggest possibility of ...
Dermatofibroma (cutaneous fibrous histiocytoma)
2022年4月11日 · Most useful stain based on evidence is CD163; factor XIIIa is variable in dermatofibroma; CD68 and CD10 are less specific for fibrohistiocytic lineage Ki67 and PHH3 can also be used to show increased proliferation index in dermatofibroma (compared to low index in dermatofibrosarcoma protuberans) (Am J Dermatopathol 2017;39:504)
Reactive B cell rich lymphoid proliferations that can mimic …
2023年9月26日 · CD10, BCL2, BCL6, LMO2 CD43, MNDA, CD5-/+ Cyclin D1, SOX11, CD5 Common negative markers CD3, BCL2 CD5, cyclin D1 CD10, cyclin D1, SOX11 CD10-, CD23- in mantle zones Flow cytometry Polytypic Monotypic surface Ig; CD10 positive Monotypic surface Ig; CD10 neg; CD5 neg or weak Monotypic surface Ig; CD5 positive
Pathology Outlines - Eosinophilic vacuolated tumor (EVT)
2025年2月6日 · PAX8, AE1 / AE3, CD10 and antimitochondrial antigens Cathepsin K and CD117 (both may be focal) SDHB and FH retained (positive) References: Mod Pathol 2021;34:1167, Mod Pathol 2022;35:344, Am J Surg Pathol 2022;46:1562
Pathology Outlines - Hematogones
2024年3月4日 · Stage 2 hematogones begin to show down regulation / negativity of TdT, CD34 and CD10; they exhibit increased expression of CD19 and CD20 with continued bright expression of CD38 and CD43, with dim expression of CD22 and CD45 and they are generally positive for cytoplasmic immunoglobulin (Leuk Res 2013;37:1404)
Pathology Outlines - Renal cell carcinoma overview
2025年1月13日 · Generally, CD10 (proximal tubular marker), RCC, vimentin and epithelial markers including AE1 / AE3, CAM 5.2, EMA; Cathepsin K (60% of TFE3 rearranged RCC) MelanA and HMB45 (50% of TFEB rearranged RCC) KIT (marker of intercalated cells), positive in chromophobe RCC and oncocytoma; Reference: Semin Diagn Pathol 2022;39:1
Pathology Outlines - PAX8
2020年10月26日 · Gene is at 2p13 (NCBI: PAX8 [Accessed 26 October 2020]) PAX8 is comprised of an N terminal DNA binding domain, an octapeptide and a C terminal DNA binding domain (Biochem J 2004;377:553)